Key result
Mavacamten improves symptoms in ~87% of oHCM patients while substantially reducing LVOT gradients.
Why the study?
Evidence on the real-world effectiveness, safety, and clinical challenges of mavacamten for obstructive hypertrophic cardiomyopathy (oHCM) was needed.
Does mavacamten improve NYHA functional class and reduce left ventricular outflow tract gradients in patients with obstructive hypertrophic cardiomyopathy in a real-world setting?
Cohort (n=82)
Yes
Does mavacamten improve NYHA functional class and reduce left ventricular outflow tract gradients in patients with obstructive hypertrophic cardiomyopathy in a real-world setting?
In the first European real-world cohort of obstructive hypertrophic cardiomyopathy patients, mavacamten provided sustained hemodynamic and symptomatic improvements over one year with an acceptable safety profile that complements clinical trial data.
Real-world mavacamten use was associated with sustained LVOTG reductions and NYHA improvement in obstructive HCM; extends trial efficacy to European routine practice.
Introduction Evidence of real-world use and challenges related to Mavacamten are much needed. The SWISS-MAVA Cohort was established to evaluate the real-world effectiveness and safety of mavacamten in the treatment of Obstructive Hypertrophic Cardiomyopathy (oHCM) in Switzerland. Methods Consecutive patients with oHCM treated with Mavacamten across 4 Swiss referral centers were included. Clinical, echocardiographic, and laboratory data were collected at baseline and during follow-up. Primary outcomes included changes in New York Heart Association (NYHA) class and left ventricular outflow tract gradients (LVOTG). Secondary outcomes addressed the evolution of LV ejection fraction (LVEF), treatment discontinuation and new-onset atrial fibrillation (AF). Results Eighty-two patients (59.5 ± 13.4 years, 37% female) were included with a mean follow-up of 52.4 ± 21.4 weeks. At baseline, 47/82 patients (57%) were in NYHA class III. Sustained reductions from baseline to last follow-up occurred in LVOTG (resting -26.5 [IQR -8; -61] mmHg; Valsalva -61 [IQR -36.8; -95] mmHg), left atrial volume indexed (-7.5 ± 4.9 ml/m2), maximal LV wall thickness (-2.4 ± 1.7 mm) and N-terminal pro B-type natriuretic peptide (Nt-proBNP, -1076 [IQR -1325.5, -208] ng/L). Mean LVEF decreased from 66.7% (baseline) to 62.5% (week 24) and remained stable (62.6%) up to last visit. At last follow-up, 65 (79.3%) had a Valsalva LVOTG <30 mmHg and 71 (86.6%) improved by at least one NYHA class from baseline with a Valsalva LVOTG <50 mmHg. Over 85.3 patient-years exposure, 5 patients (6%; exposure-adjusted incidence: 5.9/100 patient-years) experienced transient reductions in LVEF to <50% resulting in temporary treatment interruption (all recovered LVEF of ≥50% and Nt-proBNP remained stable in 4/5 cases). Treatment was permanently discontinued in one patient (1.2%), who did not fulfil Swiss reimbursement criteria within 15 months. Six patients developed new-onset AF (7%, 7.1/100 patient-years). No patients died. Conclusions In this first European real-world cohort, mavacamten demonstrated sustained symptomatic and hemodynamic relief with an acceptable safety profile over >1 year follow-up. These findings support the effectiveness and feasibility of mavacamten therapy in routine clinical practice and complement contemporary trials evidence.
No takes yet. Share an insight, caveat, or question.
Jensen et al. (2026) conducted a cohort in Obstructive hypertrophic cardiomyopathy (oHCM) (n=82). Mavacamten was evaluated on Changes in New York Heart Association (NYHA) class and left ventricular outflow tract gradients (LVOTG). Mavacamten reduced resting LVOTG by 26.5 mmHg and Valsalva LVOTG by 61 mmHg, with 86.6% of oHCM patients improving by ≥1 NYHA class over 52.4 weeks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: